

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Singel Technology Appraisal

Equality impact assessment – Scoping

Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy [ID547]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The LHON society and the Lily Foundation noted that there is inequality of access based on where people live because idebenone is available on the NHS in Scotland and Wales but not in England.

LHON is most common in men aged 15 to 35.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The NICE appraisal process will address the availability of idebenone across the UK because it will, if idebenone is found to be clinically and cost effective, make it available on the NHS to people in England.

In terms of LHON being more common in young men, issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director (name): ...Linda Landells

Date: 17 August 2023